• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美国食品和药物管理局批准当代癌症疗法后的心血管安全性通讯。

Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.

机构信息

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio.

Division of Hematology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio.

出版信息

JAMA Oncol. 2021 Nov 1;7(11):1722-1723. doi: 10.1001/jamaoncol.2021.4771.

DOI:10.1001/jamaoncol.2021.4771
PMID:34591072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8485208/
Abstract

This cohort study examines the prevalence and factors associated with postmarketing communications by the US Food and Drug Administration about cardiovascular events associated with anticancer thearpy.

摘要

本队列研究考察了美国食品和药物管理局发布的与抗癌治疗相关心血管事件的上市后通讯的流行情况及其相关因素。

相似文献

1
Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.美国食品和药物管理局批准当代癌症疗法后的心血管安全性通讯。
JAMA Oncol. 2021 Nov 1;7(11):1722-1723. doi: 10.1001/jamaoncol.2021.4771.
2
US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019.美国食品和药物管理局授权的 2015-2019 年高风险心血管器械上市后研究。
JAMA Intern Med. 2022 May 1;182(5):556-558. doi: 10.1001/jamainternmed.2022.0184.
3
Post-market drug safety evidence sources: an analysis of FDA drug safety communications.上市后药品安全性证据来源：对美国食品药品监督管理局药品安全通讯的分析
Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1134-6. doi: 10.1002/pds.3317.
4
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.美国食品和药物管理局对上市后要求和上市后承诺的利用，2009-2018 年。
Clin Trials. 2021 Aug;18(4):488-499. doi: 10.1177/17407745211005044. Epub 2021 Apr 16.
5
Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.实时肿瘤学审查适应症批准的上市前证据和上市后要求。
JAMA Netw Open. 2024 May 1;7(5):e249233. doi: 10.1001/jamanetworkopen.2024.9233.
6
The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.美国食品药品监督管理局的加速批准计划：通过加强上市后证据生成来解决上市前的灵活性问题。
Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657.
7
Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020.2006-2020 年美国食品药品监督管理局批准的疫苗上市后研究特征。
JAMA Netw Open. 2021 Apr 1;4(4):e218530. doi: 10.1001/jamanetworkopen.2021.8530.
8
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.美国食品药品监督管理局对2011 - 2017年批准的肿瘤学新分子实体的反向翻译：抗癌药物开发的经验教训
Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19.
9
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.评估新批准癌症药物上市后 2 年内的严重上市后安全信号。
Oncologist. 2020 Apr;25(4):348-354. doi: 10.1634/theoncologist.2019-0653. Epub 2019 Dec 17.
10
Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.美国食品药品监督管理局批准加速批准的疫苗的批准前和批准后研究特征。
J Gen Intern Med. 2021 Oct;36(10):3281-3284. doi: 10.1007/s11606-021-06943-x. Epub 2021 Jun 15.

引用本文的文献

1
Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the hellenic cardiac society.癌症患者及其幸存者的心律失常、传导障碍与心源性猝死：希腊心脏病学会心脏肿瘤学与电生理学工作组专家意见
Cardiooncology. 2025 Jul 28;11(1):71. doi: 10.1186/s40959-025-00363-0.
2
Understanding the Mechanism of Cardiotoxicity Induced by Nanomaterials: A Comprehensive Review.理解纳米材料诱导心脏毒性的机制：综述
Small Sci. 2025 Feb 20;5(5):2400498. doi: 10.1002/smsc.202400498. eCollection 2025 May.
3
Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.支持 FDA 批准当代癌症疗法的临床试验中女性的代表性。
Int J Cancer. 2024 Dec 1;155(11):1958-1968. doi: 10.1002/ijc.35110. Epub 2024 Aug 19.
4
Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App Into Care of Patients With Cancer: Qualitative Study of Patient and Provider Perspectives.探索将一款新型心脏毒性移动健康应用纳入癌症患者护理：对患者和医护人员观点的定性研究
JMIR Cancer. 2023 Dec 12;9:e46481. doi: 10.2196/46481.
5
Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues.癌症患者的室性心律失常：机制、治疗策略及未来方向
Arrhythm Electrophysiol Rev. 2023 May 29;12:e16. doi: 10.15420/aer.2023.04. eCollection 2023.